AA
PCRX icon

AlphaCentric Advisors’s Pacira BioSciences PCRX Stock Holding History

AlphaCentric Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-117,500
Closed -$3.36M – 237
2024
Q2 		$3.36M Hold
117,500
– – 2.48% 6
2024
Q1 		$3.43M Hold
117,500
– – 2.07% 5
2023
Q4 		$3.96M Buy
117,500
+14,500
+14% +$424K 2.66% 4
2023
Q3 		$3.16M Buy
103,000
+46,500
+82% +$1.68M 1.79% 10
2023
Q2 		$2.26M Buy
56,500
+20,500
+57% +$848K 1.26% 18
2023
Q1 		$1.47M Buy
36,000
+17,000
+89% +$676K 1.01% 24
2022
Q4 		$734K Buy
+19,000
New +$924K 0.72% 50

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

AlphaCentric Advisors's PCRX Position: Q3 2024 in Review

AlphaCentric Advisors sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 117,500 shares — an estimated $3.36M sold.

AlphaCentric Advisors first reported a position in PCRX in Q4 2022 and held it in 7 quarters. The position peaked at $3.96M in Q4 2023. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • AlphaCentric Advisors reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 117,500 Pacira BioSciences shares in Q3 2024, an estimated $3.36M.
  • AlphaCentric Advisors first reported a position in Pacira BioSciences in Q4 2022 and held it in 7 quarters.
  • AlphaCentric Advisors's Pacira BioSciences position peaked at $3.96M in Q4 2023.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.